Biotech Company Announces Successful End-of-Phase 2 Meeting With FDA For PTSD Treatment Development
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder.
Disclaimer: The following article is intended for informational purposes only and does not constitute medical, legal, or financial advice. Readers are encouraged to seek professional counsel for specific advice related to their circumstances.
Real-time information is available daily at https://stockregion.net